FibroGen Inc [FGEN] stock is trading at $0.35, up 3.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The FGEN shares have gain 7.92% over the last week, with a monthly amount drifted -21.63%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
FibroGen Inc [NASDAQ: FGEN] stock has seen the most recent analyst activity on August 08, 2023, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $2 from $4. Previously, William Blair downgraded its rating to Mkt Perform on June 26, 2023. On June 26, 2023, downgrade downgraded it’s rating to Hold. Raymond James downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to a Neutral. Stifel upgraded its rating to Buy for this stock on June 02, 2023, and upped its price target to $32. In a note dated January 31, 2023, William Blair upgraded an Outperform rating on this stock.
FibroGen Inc [FGEN] stock has fluctuated between $0.30 and $2.93 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. FibroGen Inc [NASDAQ: FGEN] shares were valued at $0.35 at the most recent close of the market. An investor can expect a potential return of 7900.0% based on the average FGEN price forecast.
Analyzing the FGEN fundamentals
FibroGen Inc [NASDAQ:FGEN] reported sales of 173.81M for the trailing twelve months, which represents a growth of 14.26%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.92%, Pretax Profit Margin comes in at -0.99%, and Net Profit Margin reading is -0.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is 0.82 and Total Capital is -1.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3385 points at the first support level, and at 0.3225 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3752, and for the 2nd resistance point, it is at 0.3959.
Ratios To Look Out For
For context, FibroGen Inc’s Current Ratio is 1.41. Also, the Quick Ratio is 1.24, while the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 0.20.
Transactions by insiders
Recent insider trading involved Adib Deyaa, Chief Medical Officer, that happened on Jun 12 ’24 when 22123.0 shares were purchased. CEO, Wettig Thane completed a deal on Mar 07 ’24 to buy 50000.0 shares.
